Summit Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -4 | -42 | -25 | |
EBITDA | 59,084 | -231,751 | -62,888 | |
EBIT | 59,188 | -231,793 | -62,913 | |
Net Income | -219,172 | -231,793 | -231,793 | -62,913 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -100,162 | -93,151 | -95,090 | -61,590 |
Cash | 225,266 | 238,554 | 238,875 | 211,526 |
Basic Shares | 747,702 | 744,442 | 743,415 | 738,076 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $704 |
Gross Profit | -108 | -15,007 | -2,050 | -1,810 |
EBITDA | -801,117 | -212,853 | -69,450 | -73,118 |
EBIT | -801,225 | -230,001 | -69,606 | -74,381 |
Net Income | -1,079,586 | -221,315 | -614,928 | -78,782 |
Net Change In Cash | 0 | 0 | 0 | 704 |
Free Cash Flow | -323,587 | -142,245 | -76,888 | -42,206 |
Cash | 225,266 | 104,862 | 71,425 | 348,607 |
Basic Shares | 747,702 | 718,542 | 619,646 | 193,336 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.39 |
2025-09-30 | -$0.23 |
2025-06-30 | -$0.12 |
